Home › Heart Diseases › NCT07333547

Registry Study for the Evaluation of High-risk Cardiac Patients by WILLEM AI-based ECG Platform

Who can join

Ages 18 and older · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* EC/IRB approval of ICF waiver prior to recruitment; otherwise, signed informed consent form by subject and investigator
* Age \> 18 years-old, with no upper limit
* Subjects undergoing standard of care electrocardiogram (ECG) of any duration from any hardware device
* All available, but at least one, legible ECG tracings in raw data format (e.g. DICOM, XML, EDF, JSON, HL7, SCP, WFDB, CSV, etc.)
* Available subject clinical data associated with the ECG
* For 12-lead ECGs, a minimum length of 10 seconds at a minimum sample frequency of 250 Hz
* For ECGs from Holters, wearables, patches, insertable cardiac monitors, telemetries, etc., a minimum length of 30 seconds at a minimum sample frequency of 200 Hz with a lead I / II or its MCL-DII lead approximation
* For prospective eligibility only:
* Signed informed consent form, unless previously waived by the EC/IRB
* Site technical viability for ECG and subject clinical data transfer (e.g. end-to-end integration following interoperability standards such as FHIR, HL7 or DICOM)

Exclusion Criteria:

* Unavailable or suboptimal quality of the raw data from the ECG signal
* Age \< 18 years-old

About the study

The WILLEM Registry is a large-scale, single-group, observational, registry study to collect continuous clinical evidence of Willem in real-world settings. Cardiovascular diseases are a major problem for public health and healthcare systems. Electrocardiograms (ECGs) are simple tests which increase diagnostic performance and early detection of cardiovascular diseases. However, its interpretation is complex, time consuming for cardiology experts, and entails high costs for healthcare systems. Willem allows AI-based automatic interpretation and its performance has been examined in previous clinical trials, but additional clinical evidence is needed for its integration in real-world clinical settings. This study will collect clinical evidence of Willem performance to detect cardiac abnormalities in ECGs from high-risk cardiac patients admitted to cardiovascular units.

What is being tested

• Willem AI ECG assessment (device)

Sponsor: Idoven 1903 S.L. · Participants: 200,000 · Started: Feb 3, 2026

Contact the study team

• Manuel Marina-Breysse, MD, PhD · Phone: +34669752391

Official record on ClinicalTrials.gov — NCT07333547

Locations in the U.S.

Conditions

• Heart Diseases

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.